Dabigatran

BreastfeedingGeriatricPediatric
  • TRADE NAME: Pradaxa (Boehringer Ingelheim)
  • INDICATIONS: Prevention of venous thromboembolic events, reduce stroke risk
  • CLASS: Anticoagulant, Thrombin inhibitor
  • HALF-LIFE: 2.5 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Antacids, Anticoagulants, Atorvastatin, Carbamazepine, Clarithromycin, Clopidogrel, Collagenase, Cyclosporine, Darunavir, Dasatinib, Deferasirox, Desirudin, Dextran, Diclofenac, Dronedarone, Fondaparinux, Heparin, Ibritumomab, Itraconazole, Ketoconazole, Ketorolac, Lapatinib, Meloxicam, Nandrolone, Neratinib, NSAIDs, P-glycoprotein inducers and inhibitors, Pantoprazole, Pentosan, Phenytoin, Polysulfate sodium, Prostacyclin analogues, Proton pump inhibitors, Quinidine, Rifampin, Rivaroxaban, Salicylates, St John's Wort, Sulfinpyrazone, Tacrolimus, Telaprevir, Thrombolytic agents, Ticlopidine, Tipranavir, Tositumomab & Iodine131, Ulipristal, Verapamil, Vitamin K antagonists

PREGNANCY CATEGORY: C

Contra-indicated in patients with active pathological bleeding or with a mechanical prosthetic heart valve.

DISCONTINUING PRADAXA IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE

See full prescribing information for complete boxed warning.

Our database has 48 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 04/26/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top